Search

News Cardiovascular Interventions with Continued Therapy with Dabigatran −⁠ Insights from the GLORIA-AF Study

An analysis using data from an international registry of patients with newly diagnosed atrial fibrillation evaluated the safety and efficacy of continued therapy with dabigatran during cardioversion or atrial fibrillation ablation, pacemaker implantation, and coronary angiography with possible stent implantation.

Source: Anticoagulant Treatment 12. 1. 2023

News Medium to Long-term Results of PFC Sigma Total Knee Arthroplasty

The PFC Sigma knee implant was introduced in 1997. It is the most commonly used system for total knee arthroplasty in England and Wales, accounting for 34.9% of primary implantations in 2006. Studies evaluating medium to long-term implantation outcomes have shown that it is an implant with a high survival rate, low re-implantation rate, and very good clinical results.

Source: Large Joints 23. 11. 2020

News Should We Test for Alpha-1-Antitrypsin in All COPD Patients?

Approximately 1–2% of patients with chronic obstructive pulmonary disease (COPD) have an alpha-1-antitrypsin (AAT) deficiency. This is an underdiagnosed genetic disorder that leads to rapid progression of COPD, although it is initially amenable to therapeutic intervention. Therefore, it is necessary to improve early detection of affected individuals. General practitioners can play a crucial role in this process.

Source: Deficiency of Alpha-1-Antitrypsin 10. 2. 2020

Články časopisu Bone manifestations of thyroid disorders

Author of the article: Bakos Bence, Takács István, Stern H. Paula, Lakatos Péter Source: Clinical Osteology | 3/2018 14. 5. 2019

News Do ACE Inhibitors Have a Protective Effect in People with COVID-19?

Although the COVID-19 pandemic has not lasted even a year, a number of studies have already been processed, examining the influence of various factors on the morbidity and mortality of patients. The presented meta-analysis investigated the influence of ACE inhibitors on the mortality of patients with this disease.

Source: ACE inhibitory 25. 2. 2021

News Genuair®/Pressair® Inhaler in the Treatment of COPD –⁠ Minimum Errors During Inhalation and High Patient Satisfaction

The article by German authors summarizes the results achieved with the Genuair® inhaler (marketed in the USA under the name Pressair®), highlighting its ease of use, simple patient training, low error rates during inhalation compared to other inhalers, and high patient satisfaction and willingness to continue treatment.

Source: Treatment of Asthma and COPD 29. 3. 2021

News Venetoclax Treatment Strategies in Patients with CLL

One of the new targeted preparations in the treatment of chronic lymphocytic leukemia (CLL) is the Bcl-2 inhibitor venetoclax. Its significant advantage is the potential to achieve deep remission, including undetectable minimal residual disease (MRD). Unlike other targeted drugs, it can be administered for a limited period of time. The following text presents current data from clinical trials and information on the strategy of selecting and sequencing targeted CLL treatment.

Source: Chronic Lymphocytic Leukemia 20. 4. 2022

News Mucormycosis Associated with COVID-19 –⁠ Case Report and Review of Current Knowledge

Systemic corticosteroids are among the treatments used for patients with severe COVID-19. These patients are at increased risk of opportunistic bacterial and fungal infections. Pulmonary aspergillosis is particularly serious, while mucormycosis is relatively rare.

Source: Anti-Infectives 20. 10. 2021

News Infographic and Commentary from Practice: Reasons and Pathways for Patients to Biological Treatment of Asthma

For asthma patients with the most severe forms of the disease to access targeted biological treatment, they must undergo examination at one of the specialized centers for severe asthma. To facilitate this pathway, a recommended procedure has been issued, from which we present a pragmatic extract for practice in the form of a clear infographic.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 28. 4. 2023

News Romosozumab vs. Teriparatide in Sequential Treatment of Osteoporosis in Women with a History of Fracture

The STRUCTURE study observed the effect of romosozumab and teriparatide on bone density in postmenopausal women with osteoporosis transitioning from bisphosphonate treatment over a 12-month period.

Source: Osteoporosis – Trends in Sequential Therapy 14. 11. 2023

News Combination of SGLT2 inhibitors with metformin in terms of mechanism of action

In the treatment of type 2 diabetes (T2D), metformin is recommended as the first-line drug alongside lifestyle modification. However, with disease progression, monotherapy is often insufficient. SGLT2 inhibitors (SGLT2i) are recommended in combination with metformin in light of recent findings, as their mechanism of action is independent of insulin effect. They have shown a reduction in cardiovascular (CV) risk in diabetics with CV disease.

Source: Diabetes 18. 3. 2020

News Targeted Treatment of HER2-Positive Breast Tumors –⁠ Updates from ESMO 2020 Congress

The recent European Society for Medical Oncology (ESMO) Congress took place virtually. We bring you a brief summary of the presentations related to the treatment of HER2-positive breast tumors.

Source: Breast Carcinoma 11. 1. 2021

News Post hoc Analysis of the FRAME Study –⁠ Romosozumab in the Treatment of Osteoporosis in the European Population

An interesting finding from the FRAME study, which evaluated the treatment of postmenopausal women with osteoporosis using romosozumab, was the significant differences in fracture incidence among patients from various geographic regions. The following post hoc analysis specifically focused on data from European women.

Source: Osteoporosis – Trends in Sequential Therapy 14. 11. 2023

News Incidence of CV Events, Malignancies, and Venous Thromboembolism in Patients with RA According to Baseline CV Risk and Administered Treatment

An international team of experts evaluated the impact of cardiovascular (CV) risk on the incidence and risk of major CV events, malignancies, and venous thromboembolism (VTE) in patients with rheumatoid arthritis (RA) treated with tofacitinib compared to tumor necrosis factor (TNF) inhibitors, depending on the level of CV risk at the initiation of this therapy. The authors used data from the ORAL Surveillance study.

Source: Arthritis 27. 7. 2022

News Administration of aPCC as a Prevention of Bleeding After Major Cardiac Surgical Procedures

The possibility of actively preventing severe bleeding after a major cardiac surgical procedure using cardiopulmonary bypass (CPB) by administering a concentrate of activated procoagulant complex seems feasible, although a larger study will be needed to confirm its effect.

Source: Hemophilia 22. 11. 2021